<mets:mets xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" OBJID="eprint_63289" LABEL="Eprints Item" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:mets="http://www.loc.gov/METS/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mets:metsHdr CREATEDATE="2026-06-17T00:28:24Z"><mets:agent ROLE="CUSTODIAN" TYPE="ORGANIZATION"><mets:name>Arxiv Universal Publishings</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_63289_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>Expression of p53 and CD31 in Malignant Salivary Gland Tumors: A Clinicopathological and Immunohistochemical Study</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Daniyar Anarbaevich</mods:namePart><mods:namePart type="family">Nishanov1</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Otabek Bakhtiyorovich</mods:namePart><mods:namePart type="family">Abdurakhmonov2</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Murod Sarvarovich</mods:namePart><mods:namePart type="family">Khudayorov2</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Umidjon Abduganiyevich</mods:namePart><mods:namePart type="family">Soatov3</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Background: Salivary gland malignancies represent a diagnostically and therapeutically challenging group of head and neck tumors. Immunohistochemical biomarkers such as p53, CD31, VEGFR, and Ki-67 are essential in assessing the proliferative and angiogenic activity of these neoplasms.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; To evaluate the expression patterns of p53 and CD31 in malignant salivary gland tumors (MSCTs) and determine their diagnostic, prognostic, and clinical implications.Seventy patients diagnosed with MSCTs between 2017–2022 were analyzed. Immunohistochemical studies were conducted on 40 selected cases (20 mucoepidermoid carcinomas and 20 adenocarcinomas) using Bond Leica (Australia) processors with antibodies against p53, CD31, Ki-67, and VEGFR. Expressions were semi-quantitatively evaluated using the Allred scoring system.p53 expression in mucoepidermoid carcinoma was low in 70%, moderate in 20%, and high in 10% of cases, while adenocarcinomas showed low in 10%, moderate in 20%, and high in 70%. For CD31, 100% of mucoepidermoid tumors exhibited weak vascular density (10–15 vessels/field), whereas adenocarcinomas displayed strong vascularity (30–40 vessels/field).&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Adenocarcinomas of the salivary glands demonstrate significantly higher proliferative and angiogenic activity compared to mucoepidermoid carcinomas. p53 and CD31 can serve as reliable prognostic indicators for tumor aggressiveness and metastatic potential.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-11-03</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_63289"><mets:rightsMD ID="rights_eprint_63289_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Arxiv Universal Publishings the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Arxiv Universal Publishings does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Arxiv Universal Publishings is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec><mets:fileGrp USE="reference"><mets:file OWNERID="https://arxiv.universalpublishings.com/id/eprint/63289/1/main.bin" ID="eprint_63289_9620_1" MIMETYPE="application/xml" SIZE="176"><mets:FLocat LOCTYPE="URL" xlink:type="simple" xlink:href="https://arxiv.universalpublishings.com/id/eprint/63289/1/main.bin"></mets:FLocat></mets:file><mets:file OWNERID="https://arxiv.universalpublishings.com/id/eprint/63289/1/5495_11844.pdf" ID="eprint_63289_9620_2" MIMETYPE="application/pdf" SIZE="280485"><mets:FLocat LOCTYPE="URL" xlink:href="https://arxiv.universalpublishings.com/id/eprint/63289/1/5495_11844.pdf" xlink:type="simple"></mets:FLocat></mets:file></mets:fileGrp></mets:fileSec><mets:structMap><mets:div DMDID="DMD_eprint_63289_mods" ADMID="TMD_eprint_63289"><mets:div><mets:fptr FILEID="eprint_63289_document_9620_1"></mets:fptr></mets:div><mets:div><mets:fptr FILEID="eprint_63289_document_9620_2"></mets:fptr></mets:div></mets:div></mets:structMap></mets:mets>